On July 4, 2023, Nanjing RegeneCore Biotech Co., Ltd. successfully administered the first dose of its self-developed recombinant anti-human IL-4Rα/IL-5 bispecific antibody injection (RC1416 injection) to a volunteer at China-Japan Friendship Hospital. This milestone marks Nanjing RegeneCore's entry into the clinical research phase for antibody drug development. The study aims to evaluate the safety and tolerability of RC1416 in Chinese healthy subjects.

RC1416 is Nanjing RegeneCore's first bispecific antibody drug developed based on sdAb technology. By blocking the IL-4, IL-5, and IL-13 signaling pathways, it holds potential for treating diseases associated with overactivation of the Th2-type immune response.

Nanjing RegeneCore continues to advance technology innovation driven by clinical needs and market demand, steadfastly progressing on its mission to "safeguard human health with exceptional medicines."

On September 9, Nanjing Regenecore RT2831 project was approved by the State Food and Drug Administration for clinical trial research. This is the second regional (China) clinical trial approval document after the US Food and Drug Administration (FDA) approved the clinical trial license.

Nanjing Regenecore RT2831 project is a bispecific sdAb drug targeting specific antigens on the surface of malignant blood tumor cells, which has shown excellent safety and efficacy in non clinical studies. Nanjing Regenecore will soon carry out clinical research on RT2831 project in China.